Kolon TissueGene (A950160) Q2 2024 earnings summary

Executive summary

• Focuses on cell and gene therapy development, with TG-C as the lead product for osteoarthritis, currently in Phase 3 clinical trials in the US.

• Also operates a health & beauty distribution business in Korea.

• Significant R&D investment and ongoing expansion of therapeutic indications.

Financial highlights

• 2024 H1 revenue: $1.62M (USD), down from $2.84M in 2023 H1.

• Operating loss for 2024 H1: $(7.18)M, improved from $(15.71)M in 2023 H1.

• Net loss for 2024 H1: $(6.76)M, compared to $(13.00)M in 2023 H1.

• Cash and equivalents at June 30, 2024: $25.4M.

• Equity capital increased via new share issues and convertible bonds.

Outlook and guidance

• Plans to file for FDA approval (BLA) for TG-C after completion of 2-year follow-up on Phase 3 patients.

• Pipeline expansion into hip osteoarthritis (Phase 2) and degenerative disc disease (Phase 1).

• Continued focus on R&D and clinical development, with additional capital raised for ongoing trials.